Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 407 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Events Clear all
Terminated Phase 3 Interventional

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

NCT00134264
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 75 Years
Enrollment
15,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 7, 2026, 2:53 PM EDT
Completed No phase listed Observational

Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)

NCT07615179
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions
Alirocumab, Comparator: No PCSK9i Therapy (either mAb or siRNA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
4,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 7, 2026, 2:53 PM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 7, 2026, 2:53 PM EDT
Recruiting No phase listed Observational

ATHNdataset Registry

NCT06820515
View directory record Official record
Conditions
Hemophilia, Thrombosis, Hemophilia A, Hemophilia B, Sickle Cell Disease, Glanzmann Thrombasthenia, Bleeding Disorder, Blood Disorder, Von Willebrand Diseases
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
200,000 participants
Timeline
2024 – 2055
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 2:53 PM EDT
Recruiting Not applicable Interventional

Positive Emotions Following Acute Cardiac Events

NCT05412862
View directory record Official record
Conditions
Acute Coronary Syndrome, Physical Inactivity
Interventions
Positive Psychology + Motivational Interviewing
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Not applicable Interventional

Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE

NCT00180492
View directory record Official record
Conditions
Atherosclerotic Disease, Carotid
Interventions
RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2008 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

NCT02019264
View directory record Official record
Conditions
Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions
Lorcaserin hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years and older
Enrollment
14,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
373
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

NCT01994720
View directory record Official record
Conditions
Acute Ischaemic Stroke, Transient Ischaemic Attack
Interventions
ticagrelor, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
13,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
115
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 7, 2026, 2:53 PM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population

NCT00431405
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease, Coronary Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2007 · Synced Sep 7, 2026, 2:53 PM EDT
Terminated Not applicable Interventional

Positive Emotions After Acute Coronary Events at Northwestern University

NCT04062383
View directory record Official record
Conditions
ACS - Acute Coronary Syndrome
Interventions
Positive Psychology + Motivational Interviewing
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 7, 2026, 2:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation

NCT02311270
View directory record Official record
Conditions
Metabolic Disorders
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event

NCT01578629
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions
Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin, Placebo vehicle control
Other
Lead sponsor
Andrew Slivka
Other
Eligibility
40 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 7, 2026, 2:53 PM EDT
Withdrawn No phase listed Observational

ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study

NCT02265146
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
5
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

NCT00391872
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
18,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

NCT00548587
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Beloit, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 7, 2026, 2:53 PM EDT
Terminated Phase 3 Interventional Results available

Phase III Acute Coronary Syndrome

NCT00831441
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
7,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 7, 2026, 2:53 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975389
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
518
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Sep 7, 2026, 2:53 PM EDT
Recruiting Phase 3 Interventional

Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass

NCT06702553
View directory record Official record
Conditions
Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions
Nitric Oxide Gas, Standard Care Arm
Drug
Lead sponsor
Xijing Hospital
Other
Eligibility
18 Years and older
Enrollment
3,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
6,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 7, 2026, 2:53 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 7, 2026, 2:53 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
24
States / cities
Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 7, 2026, 2:53 PM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 7, 2026, 2:53 PM EDT
Recruiting No phase listed Observational

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT06151730
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 2:53 PM EDT